arrow
M

Marcos de Lima

The Ohio State University
H指数:84
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Decentralized CAR-T production: clinical, economic, and regulatory perspectives. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article

去中心化CAR-T生产:临床、经济和监管视角。世界血液与骨髓移植网络(WBMT)专题文章

2026-09-240
PRE
Spatial tissue analysis of secondary sarcoma following CAR T cell therapy for B cell lymphoma

B细胞淋巴瘤CAR T细胞疗法后继发性肉瘤的空间组织分析

2026-07-010
PRE
Phase I Trial of Venetoclax and BEAM Followed by Autologous Stem Cell Transplant for High-Risk Non-Hodgkin Lymphoma

静脉注射硼替佐米、白蛋白结合型紫杉醇和地塞米松(VAD)方案治疗复发/难治性多发性骨髓瘤的I期临床试验

2026-03-270
PRE
BET inhibition blunts antibody production and macrophage mediated fibrosis to restore lung function in murine cGVHD

BET抑制可减弱抗体产生及巨噬细胞介导的纤维化,从而恢复小鼠cGVHD的肺功能。

Blood
IF23.1
2026-03-040
OAAI
Outcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell transplant: a plain language summary

接受伊诺妥珠单抗治疗并在干细胞移植前的急性淋巴细胞白血病患者结局:简易语言摘要

2025-12-070
OAAI
Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in new era: A CIBMTR study

异基因造血细胞移植在新时代晚期系统性肥大细胞增生症中的应用:一项CIBMTR研究

2025-09-220
PRE
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis

CD19 CAR T细胞疗法治疗原发性纵隔大B细胞淋巴瘤:一项CIBMTR分析

2025-08-110
PRE
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies

血液恶性肿瘤患者接受CAR T细胞疗法后的第二原发恶性肿瘤

2025-03-180
OA
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial

使用现场制备的CAR T细胞治疗非霍奇金淋巴瘤:一项双中心、1期临床试验

2025-03-010
OAAI
Five-Year Real-World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B-Cell Precursor Acute Lymphoblastic Leukemia

在B-细胞前体急性淋巴细胞白血病中,伊诺妥珠单抗在造血干细胞移植前的五年真实世界安全性

2025-02-240
OAAI
Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

急性髓系白血病异基因移植前的可测量残留NPM1突变

BLOOD
IF23.1
2024-11-050
PRE
Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

比较两种骨髓清除性全身照射(MAC-TBI)方案:用于成人血液系统恶性肿瘤异基因干细胞移植的1200 Cgy与800 Cgy TBI剂量比较

BLOOD
IF23.1
2024-11-050
PRE
GATA2-Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation

GATA2突变AML:接受或不接受异基因干细胞移植患者的临床结局及感染谱

BLOOD
IF23.1
2024-11-050
PRE
MO-TRANS: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Mocravimod (MOC) As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

MO-TRANS:一项关于莫克拉维莫德(MOC)作为辅助和维持治疗的随机、双盲、安慰剂对照、多中心III期研究,用于接受异基因造血细胞移植的AML患者

BLOOD
IF23.1
2024-11-050
PRE